Ketorolac and Metoclopramide for Migraine in the ED Ketorolac and Metoclopramide for Migraine in the ED
Is this combination therapy an effective strategy for the acute treatment of pediatric migraine in the ED?Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Risk for Ischemic Stroke Up With Antidopaminergic Antiemetic Use
Increase in risk greatest for metopimazine and metoclopramide; risk for ischemic stroke may be higher in first days of use (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2022 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Gastroenterology, Internal Medicine, Neurology, Oncology, Pharmacy, Journal, Source Type: news

Drug Combo Superior to Placebo for Posttraumatic Headache
THURSDAY, March 25, 2021 -- For patients with acute posttraumatic headache presenting to the emergency department, intravenous metoclopramide + diphenhydramine (M+D) is more efficacious than placebo, according to a study published online March 24 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2021 Category: Pharmaceuticals Source Type: news

Metoclopramide inhibits proliferation of leukemia stem cells
(Inselspital, Bern University Hospital) A research team at Inselspital, Bern University Hospital and the University of Bern has identified and tested the use of an agent that can effectively inhibit the proliferation of leukemia stem cells. Metoclopramide (MPR), used as an anti-emetic medication, interrupts the unique CD93 signaling pathway that only leukemia stem cells use to proliferate. This opens up a therapeutic approach using MPR to selectively eliminate leukemia stem cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 26, 2021 Category: International Medicine & Public Health Source Type: news

Gimoti (Metoclopramide Nasal Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 25, 2021 Category: Drugs & Pharmacology Source Type: news

Gimoti (Metoclopramide Nasal Spray) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Metoclopramide Nasal Spray for Diabetic Gastroparesis FDA Approves Metoclopramide Nasal Spray for Diabetic Gastroparesis
The product, called Gimoti, delivers metoclopramide through nasal administration, offering an advantage over oral administration.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 24, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Gimoti (metoclopramide) Nasal Spray for Diabetic Gastroparesis
SOLANA BEACH, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2020 Category: Drugs & Pharmacology Source Type: news

Ondansetron (Zofran) vs. metoclopramide (Reglan)
Title: Ondansetron (Zofran) vs. metoclopramide (Reglan)Category: MedicationsCreated: 7/26/2019 12:00:00 AMLast Editorial Review: 7/26/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 26, 2019 Category: Drugs & Pharmacology Source Type: news

metoclopramide, Reglan, Metozolv ODT, (Reglan ODT, Octamide, and Maxolon
Title: metoclopramide, Reglan, Metozolv ODT, (Reglan ODT, Octamide, and MaxolonCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/2/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - July 2, 2019 Category: Nutrition Source Type: news

FDA nixes Evoke Pharma ’s gastro nasal spray
The FDA has rejected Evoke Pharma’s (NSDQ:EVOK) application for a metoclopramide nasal spray for diabetic women with gastroparesis. The Solana Beach, Calif. company’s stock price tumbled 40% on the news yesterday that the agency had found dosing inconsistencies in the pivotal pharmacokinetic study for the spray, Gimoti. In an earlier multi-disciplinary letter to the company, the FDA had cited concerns with quality control, dosing, and a lack of information to support sex-based differences in efficacy. Get the full story on our sister site, Drug Delivery Business. (Source: Mass Device)
Source: Mass Device - April 3, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Business/Financial News Drug-Device Combinations Food & Drug Administration (FDA) News Well Pharma Pharmaceuticals Regulatory/Compliance Women's Health evokepharma Source Type: news

Occipital Nerve Blocks With Bupivacaine for Acute Migraine Occipital Nerve Blocks With Bupivacaine for Acute Migraine
Is greater occipital nerve block an effective treatment for acute migraine in patients who fail to improve after first-line treatment with intravenous metoclopramide?Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Metoclopramide Injection, USP (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - November 6, 2017 Category: Drugs & Pharmacology Source Type: news

Metoclopramide Injection, USP (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 24, 2017 Category: Drugs & Pharmacology Source Type: news

Metoclopramide Injection, USP (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 23, 2017 Category: Drugs & Pharmacology Source Type: news